Palisade Bio (NASDAQ:PALI) Trading 1.5% Higher

Shares of Palisade Bio, Inc. (NASDAQ:PALI) shot up 1.5% on Thursday . The stock traded as high as $5.15 and last traded at $4.76. 56,094 shares changed hands during trading, a decline of 92% from the average session volume of 693,561 shares. The stock had previously closed at $4.69.

Analyst Upgrades and Downgrades

Separately, Maxim Group restated a “buy” rating and set a $22.50 price objective on shares of Palisade Bio in a report on Wednesday, May 1st.

Palisade Bio Trading Up 1.5 %

The firm’s 50 day moving average price is $5.55 and its two-hundred day moving average price is $6.70. The company has a market capitalization of $4.47 million, a price-to-earnings ratio of -0.20 and a beta of 1.24.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Monday, May 13th. The company reported ($4.59) EPS for the quarter. As a group, equities research analysts predict that Palisade Bio, Inc. will post -10.81 EPS for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.